GlobeNewswire

SoftServe Partners with Ultrahaptics to Innovate Next Generation Virtual Touch Technology

Dela

Precision controlled ultrasound waves create sensations in mid-air, allowing users to intuitively feel virtual shapes and textures

AUSTIN, Texas, July  25, 2018  (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has become an Agency Partner with the world's leading mid-air haptics company, Ultrahaptics.

Haptics is a unique technology that enables users to receive tactile feedback without needing to wear or touch anything. Ultrahaptics' technology precisely controls ultrasound waves to create a range of shapes and sensations in mid-air. This can create haptics for virtual objects, develop immersive holographic interfaces, and augment gesture control with natural tactile feedback.

As an agency partner, SoftServe will get early access to Ultrahaptics' STRATOSTM Explore, the most advanced mid-air haptics device on the market, enabling SoftServe the company to create cutting edge demos and prototypes. SoftServe and its clients will gain access to the latest, most powerful haptics solutions for marketing and innovation in augmented reality (AR) and virtual reality (VR) projects. Additionally, SoftServe can leverage use cases, design and technology training, UX insights and design guidelines for haptics as part of multi-sensory experience design.

"Working at the cutting edge of technologies like voice control, AI, AR and VR innovation, SoftServe is an experience design pioneer," said Anders Hakfelt, VP Product and Marketing at Ultrahaptics. "As an Ultrahaptics agency partner, they are helping to unleash the full creative potential of designers and product developers, transforming the future of how society interacts with the world."

STRATOS Explore is a high-end development kit for advanced haptics applications and use cases. Ultrahaptics' patented algorithms control ultrasound waves to create haptic sensations in mid-air - shapes and objects that cannot be seen, but can be felt. No controllers or wearables are needed; the "virtual touch" technology uses ultrasonic transducers to project sensations directly onto the user's hands. This has tremendous implications for automotive, location-based entertainment, digital signage, AR/VR, computing and gaming, smart homes, kiosks and ATMs, and industrial and medical applications.

"Being an agency partner with Ultrahaptics enables SoftServe to leverage a competitive edge for our customers," said Serge Haziyev, SVP of Advanced Technology at SoftServe. "We are going to introduce consumers to a new level of touch for immersive solutions, from keeping medical environments as sterile as possible to touching clothes in a virtual fitting room when shopping online, combining SoftServe's unmatched R&D innovation and a human-focused approach."

SoftServe is currently planning to develop and showcase demos and prototypes for a retail AR customizer at upcoming events such as CES, SXSW, AWE, and FinTech Connect.

For more information on Ultrahaptics, please see the company's press kit.

About Ultrahaptics
Ultrahaptics is the world's leading mid-air haptics company. The company has developed a unique technology that enables users to receive tactile feedback without needing to wear or touch anything. The technology uses ultrasound to project sensations through the air and directly onto the user's hands, enabling users to 'feel' virtual buttons, get tactile feedback for mid-air gestures, or interact with virtual objects. www.ultrahaptics.com

About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, media, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients' users expect.

SoftServe delivers open innovation-from generating compelling new ideas, to developing and implementing transformational products and services.

Our work and client experience is built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release.

We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today's digital economy. No matter where you are in your journey.

Visit our websiteblogLinkedInFacebook, and Twitter pages.

SoftServe Media Contact
Paul Jones
Senior Manager, Analyst and Public Relations
pjone@softserveinc.com
512-796-7358




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SoftServe via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum